NCT05513248 is a clinical trial of anatomic lung resection in COVID-19, sponsored by Lung Center of the Philippines.

Who is sponsoring NCT05513248?

NCT05513248 is sponsored by Lung Center of the Philippines.

What drugs are being tested in NCT05513248?

Interventions in NCT05513248: anatomic lung resection.

What condition does NCT05513248 study?

NCT05513248 studies COVID-19, Lung Cancer, Lung TB, Hemoptysis.

Is NCT05513248 still recruiting?

NCT05513248 is currently completed. Last updated 9 November 2022.

Last reviewed 2022-11-09 · How we verify

NCT05513248

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Perioperative Outcomes of Anatomic Lung Resections in Patients Who Recovered From Coronavirus Disease 2019

Completed Last updated 9 November 2022

What this trial tests

trial testing anatomic lung resection in COVID-19 in 16 participants. Completed in 1 November 2022.

Timeline

10 October 2022

Primary endpoint
31 October 2022

1 November 2022

Quick facts

Lead sponsor	Lung Center of the Philippines
Status	Completed
Study type	OBSERVATIONAL
Enrollment	16
Start date	10 October 2022
Primary completion	31 October 2022
Estimated completion	1 November 2022
Sites	1 location across Philippines

Drugs / interventions tested

anatomic lung resection

Conditions studied

COVID-19 — all drugs for COVID-19 →
Lung Cancer — all drugs for Lung Cancer →
Lung TB — all drugs for Lung TB →
Hemoptysis — all drugs for Hemoptysis →

Sponsor

Lung Center of the Philippines

Who can join

Eligibility, any sex, with COVID-19 or Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will determine the outcomes of anatomic lung resections in patients who recovered from coronavirus disease 2019 (COVID-19) disease by describing the morbidity and mortality as well as the length of postoperative hospital stay.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05513248 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Lung Center of the Philippines
Last refreshed: 9 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05513248.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing